A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Completed
Bristol-Myers Squibb
Phase 3
2007-09-01
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce
blood sugar levels in participants with Type 2 diabetes that is not well controlled on
metformin alone. The safety of this treatment will also be studied.
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Completed
AstraZeneca
Phase 3
2007-09-01
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce
blood sugar levels in participants with Type 2 diabetes that is not well controlled on
metformin alone. The safety of this treatment will also be studied.
The purpose of the study is to determine the effect of metformin on dapagliflozin exposure
and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally,
the safety and tolerability of dapagliflozin will be assessed in the presence and absence of
metformin in healthy volunteers
The purpose of the study is to determine the effect of metformin on dapagliflozin exposure
and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally,
the safety and tolerability of dapagliflozin will be assessed in the presence and absence of
metformin in healthy volunteers
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
Completed
Astra Zeneca, Bristol-Myers Squibb
Phase 3
2008-06-01
The purpose of this clinical research study is to learn if initiating treatment with
BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in
patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes,
when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety
of this treatment will also be studied
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
